Effective antibiotic therapy for community-acquired otorhinolaryngological respiratory infection (clinical description)

The State Report on the state of sanitary and epidemiological well-being population in Russian Federation speaks continued growth respiratory infections, reaching more than 33 million cases amounting to 606 billion rubles direct economic damage 2021. Of particular importance is new coronavirus infection SARS-CoV-2, manifestations its various genovariants, for example, variant B.1.1.529 called omicron, causes inflammatory nosologies part mucous membranes ENT organs (acute rhinosinusitis, acute tonsillopharyngitis, otitis media). viral agent, damaging epithelium upper tract, creates favorable conditions activation microbial flora. Identification a agent most often carried out only severe disease, so basic diagnosis based clinical symptoms. relevance studying rational use antibacterial drugs treatment community-acquired infections practical otorhinolaryngology associated not with frequency occurrence, but high risk complications. As rule, are actively used complex therapy bacterial etiology tract. Due variability increasing antibiotic resistance, antimicrobial agents always rationally outpatients. In this context, as noted guidelines, one topical issues dosed accordance pharmacokinetics, pharmacodynamics efficacy prescribing cephalosporin form dispersible tablets patients diseases tract ear, an cases.